IBI38D9-L
IBI38D9-L is a human IgG1-type CD79b/CD3 bispecific T-cell engager. IBI38D9-L binds to human CD79b and CD3 with Kd values of 1.45 nM and 119 nM, respectively. IBI38D9-L mediates tumor cell recognition and T-cell engagement, activating T cells and inducing their proliferation and release of cytotoxic molecules. IBI38D9-L exerts T cell-mediated cytotoxicity in a tumor cell-dependent manner, thereby selectively depleting antigen-positive malignant B cells. IBI38D9-L can be used for research on B-cell non-Hodgkin lymphoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Species Reactivity
Human
IC50 & Target
[1]|
CD79b 1.45 nM (Kd) |
CD3 119 nM (Kd) |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOG (female, reconstituted with human PBMCs)[1]
-
Dosage:1 mg/kg
-
Administration:on days 8, 12, 15, 19, and 22
-
Result:Produced a tumor growth inhibition (TGI) of 73% at 1 mg/kg.
No body weight reduction or overt toxicities were observed.
-
Animal Model:NOG (female, reconstituted with human PBMCs)[1]
-
Dosage:3 mg/kg
-
Administration:on days 6, 9, 13, 16, and 20
-
Result:Produced a tumor growth inhibition (TGI) of 62% at 3 mg/kg.
No body weight reduction or overt toxicities were observed.
-
Animal Model:NOG (female, reconstituted with human PBMCs)[1]
-
Dosage:3 mg/kg
-
Administration:once
-
Result:Compared with control, IBI38D9-L increased tumor-infiltrating CD4+ and CD8+ T cells on both days 1 and 3 after administration.
Activated T cells (CD4+CD25+ or CD8+CD25+) were increased in tumor samples from the treated group.
Intracellular granzyme B and perforin within CD4+ and CD8+ T cells showed similar trends to CD25.
Immunofluorescence confirmed elevated CD3+ T cell infiltration in tumors from treated animals.
-
Animal Model:HSC-NPG (female, engrafted with human CD34+ hematopoietic stem cells)[1]
-
Dosage:3 mg/kg and 10 mg/kg
-
Administration:on days 0, 7, 14, and 21
-
Result:Produced a large decrease in B cells in peripheral blood at day 3 after the first dose at 3 and 10 mg/kg, with almost no B cells detected on day 10 and thereafter.
No loss of CD3+ T cells was observed at day 3; however, almost no CD3+ T cells were detected at day 10 onwards.
Target
CD79b & CD3
Conjugated
Unconjugated
Application
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[IBI38D9-L]
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IBI38D9-L Related Classifications
HY-P992547 Related Classifications
Powered by Bioz